undamentalytics Newsletter
Sign in

Beta Bionics, Inc. income statement

In fiscal 2025, Beta Bionics, Inc. reported revenue of $100m, up 53.9% on the year before, operating income of −$71.7m (a -71.5% margin) and net income of −$73.2m, or −$1.81 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue1265100127
Cost of revenue6294553
Gross profit6365675
Research and development18263543
Selling and marketing12376187
General and administrative12183138
Operating income−36−45−72−93
Income tax—00—
Net income−44−55−73−83
Diluted EPS−$8.31−$8.60−$1.81−$1.85
Diluted shares (average)5m6m41m45m
EBITDA−35−44−70−90

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BBNX vs RXSTANIK vs BBNXBBNX vs OMBBNX vs INFU

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Beta Bionics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Beta Bionics, Inc.